Nan Fung Group Holdings Ltd Makes New $34.81 Million Investment in Maplight Therapeutics, Inc. $MPLT

Nan Fung Group Holdings Ltd purchased a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 971,253 shares of the company’s stock, valued at approximately $34,809,708. Maplight Therapeutics accounts for 0.0% of Nan Fung Group Holdings Ltd’s portfolio, making the stock its largest holding. Nan Fung Group Holdings Ltd owned approximately 2.28% of Maplight Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in MPLT. Strs Ohio bought a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Maplight Therapeutics in the fourth quarter valued at about $70,000. New York State Common Retirement Fund bought a new stake in Maplight Therapeutics during the 4th quarter valued at $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $172,000. Finally, Walleye Capital LLC purchased a new position in Maplight Therapeutics during the fourth quarter valued at $205,000.

Maplight Therapeutics Trading Down 0.8%

MPLT traded down $0.10 on Friday, hitting $12.44. 196,536 shares of the company’s stock traded hands, compared to its average volume of 465,547. The company’s 50 day simple moving average is $24.29 and its 200-day simple moving average is $24.17. The firm has a market cap of $576.97 million and a price-to-earnings ratio of -0.29. Maplight Therapeutics, Inc. has a one year low of $9.10 and a one year high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last posted its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.40) by $0.08. As a group, equities analysts anticipate that Maplight Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Insider Buying and Selling at Maplight Therapeutics

In related news, insider James Woodruff Lillie sold 22,082 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total value of $276,908.28. Following the completion of the sale, the insider owned 202,380 shares in the company, valued at approximately $2,537,845.20. This represents a 9.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox acquired 15,620 shares of the company’s stock in a transaction dated Tuesday, July 28th. The stock was acquired at an average price of $9.52 per share, with a total value of $148,702.40. Following the purchase, the director owned 15,620 shares in the company, valued at approximately $148,702.40. This represents a ? increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

MPLT has been the topic of several recent research reports. Benchmark reaffirmed a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, June 22nd. Lifesci Capital upgraded Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Raymond James Financial set a $31.00 target price on Maplight Therapeutics in a report on Friday, August 14th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, July 27th. Finally, Canaccord Genuity Group set a $21.00 price objective on shares of Maplight Therapeutics in a report on Friday, August 14th. Four equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.